AbbVie Collaborates with Sosei Heptares to Develop Small Molecules for Neurological Conditions

By Ashish Tripathi

Pharma Deals Review: Vol 2022 Issue 8 (Table of Contents)

Published: 12 Aug-2022

DOI: 10.3833/pdr.v2022.i8.2714     ISSN: 1756-7874

Section: Research & Development



In a bid to bolster its pipeline, AbbVie has partnered with Sosei Heptares to develop and commercialise small molecules that modulate new G protein-coupled receptor (GPCR) targets associated with neurological disease...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details